Current Neurology and Neuroscience Reports

, Volume 11, Issue 1, pp 52–60

Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel

Authors

  • Megan M. Donohue
    • Department of NeurologyHarborview Medical Center
    • Department of NeurologyHarborview Medical Center
Article

DOI: 10.1007/s11910-010-0157-8

Cite this article as:
Donohue, M.M. & Tirschwell, D.L. Curr Neurol Neurosci Rep (2011) 11: 52. doi:10.1007/s11910-010-0157-8

Abstract

Our knowledge of the pharmacogenetics of warfarin and clopidogrel continues to expand as we learn more about the individual genetic variations that contribute to the drugs’ efficacy and toxicity. We aim to review the recent developments in the field and discuss the clinical implications for the treatment of ischemic stroke patients. Despite recent advances, there is still insufficient data to suggest that routine genetic testing improves outcomes in patients treated with warfarin or clopidogrel for prevention of stroke.

Keywords

Pharmacogenetics Warfarin Clopidogrel Testing Primary stroke prevention Secondary stroke prevention Polymorphism Resistance Variant Anticoagulation Platelet response Drug response Safety CYP2C19 CYP2C9 VKORC1 Treatment algorithm ABCB1 P2RY12

Copyright information

© Springer Science+Business Media, LLC 2010